News and events

Select providers now have access to Haystack MRD® via OncoEMR MPI capability
We are excited to announce the launch of a pilot program between Haystack MRD® by Quest Diagnostics® and OncoEMR! Select providers now have access to Haystack MRD via OncoEMR MPI capability – meaning that you may be able to order

Haystack MRD® receives New York State approval
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has officially approved Haystack MRD® for use in identifying residual or recurring disease in patients with solid tumor cancers.

Precision Oncology Exchange with Dr TJ Slavin
The Precision Oncology Exchange with TJ is a new webinar series that serves as an interactive Q&A forum designed to explore recent oncology research and real-world clinical applications.

Webinar: How ctDNA can assist in critical nonoperative management decisions
Watch an in-depth discussion with Dr Andrea Cercek, lead author of the study, and Dan Edelstein, Vice President and General Manager of Haystack Oncology at Quest Diagnostics, exploring how these results are reshaping cancer care—and what they mean for patients,

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Haystack MRD® test for identifying MRD-positive patients with stage II colorectal
Recent events

Meet us at San Antonio Breast Cancer Symposium 2026
Join us at the 2026 San Antonio Breast Cancer Symposium (SABCS) as we share how Quest Diagnostics can operationalize your precision oncology vision for breast cancer care.

Meet us at ESMO 2026
Visit the Quest Diagnostics booth #8002 | 23-27 October | Madrid, Spain
Join us at the 2026 European Society for Medical Oncology (ESMO) Congress as we share how Haystack

Bringing Confidence to ASCO 2026
We’re proud to be part of the 2026 American Society of Clinical Oncology (ASCO®) annual meeting, where we’ll present 2 posters featuring new clinical data using Haystack technology.